Interview: Medtech’s Unique Market-Access Routes Demand Tailored Response For EU-Wide HTA
Executive Summary
The European Commission is looking at initiatives for employing health technology assessment at the EU level. But the medtech industry is concerned that its own specific market-access routes are being overlooked while the commission focuses too narrowly on solutions more suited to the pharma industry. MedTech Europe’s Yves Verboven explains the industry's case in an interview.
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.